XML 24 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities    
Net loss $ (31,853) $ (37,894)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 155 236
Amortization of right-of-use assets, operating leases 687 637
Non-cash interest expense 603 82
Amortization of debt discount 35 26
Costs Expensed Upon The Issuance Of Warrants 0 549
Change in fair value of warrant liabilities 3,177 3,279
Stock-based compensation 1,925 988
Loss on issuance of warrants 0 3,502
Gain on disposal of property and equipment, net 0 (3)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,043 (580)
Other long-term prepaid assets (170) 2,233
Accounts payable (717) (2,385)
Accrued expenses (3,202) 1,095
Deferred research obligation (1,169) 613
Operating lease liabilities (669) (702)
Net cash used in operating activities (30,155) (28,324)
Cash flows from investing activities    
Purchases of property and equipment 0 (42)
Proceeds from sale of property and equipment 0 3
Net cash used in investing activities 0 (39)
Cash flows from financing activities    
Proceeds from issuance of related party convertible note 0 19,727
Proceeds from issuance of common stock and common warrants from the January 2025 Offering 9,143 0
Proceeds from issuance of common stock and common warrants 0 22,882
Proceeds from the exercise of common warrants 1,293 0
Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs 11,385 0
Proceeds from the June 2025 Promissory Note, net of issuance costs 9,866 0
Payment of warrant issuance costs 0 (549)
Proceeds from the exercise of stock options 145 34
Net cash provided by financing activities 31,832 42,094
Effect of foreign currency on cash and cash equivalents 144 (5)
Net increase in cash and cash equivalents 1,821 13,726
Cash, cash equivalents and restricted cash at the beginning of the period 19,492 14,301
Cash, cash equivalents, and restricted cash at the end of the period 21,313 28,027
Components of cash and cash equivalents, and restricted cash    
Cash and cash equivalents 20,611 26,016
Restricted cash 702 2,011
Total cash, cash equivalents and restricted cash 21,313 28,027
Supplemental disclosure of noncash investing and financing activities:    
Fair value of pre-funded warrants at issuance date 0 13,382
Fair value of common stock warrants upon settlement 2,128 0
Fair value of common warrants issued with January 2025 Offering 9,719 0
Fair value of common warrants issued with June 2025 Promissory Note 641 0
Fair value of common warrants at issuance date 0 6,509
Conversion of related-party senior note payable and interest into equity 20,176 0
Accretion of convertible notes discount from issuance costs 0 26
Vesting of restricted common stock $ 0 $ 25